Riskpilot← Back to searchSign inGet full accessK/S BI BIOMEDICAL VENTURE IV
K/SActiveCVR 28301022Bredgade 40Other financial service activities, except insurance and pension funding n.e.c. · NACE 6499Est. 2004— employees
Revenue 2024
DKK 0
EBITDA margin
—
Equity ratio
100.0%
Financial strength
Net profit 2024
DKK 0
| Revenue | DKK 0 | — |
| EBITDA | DKK 0 | — |
| Net profit | DKK 0 | — |
| Total assets | DKK 8K | +0% |
| Equity | DKK 8K | +0% |
| Employees | — | — |
Legal name
K/S BI BIOMEDICAL VENTURE IV
CVR number
28301022
Legal form
Kommanditselskab
NACE code
6499 · Other financial service activities, except insurance and pension funding n.e.c.
Founded
16. december 2004
Share capital
—
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af komplementaren
Company purpose
Selskabets formål er at foretage investeringer i K/S BI BIOMEDICAL VENTURE ANNEX I,II og III samt sådanne selskabet, som K/S BI BIOMEDICAL VENTURE ANNEX I, II og III investerer i. K/S BI BIOMEDICAL VENTURE ANNEX I, II og III\'s formål er at foretage investeringer i ejerandele i, herunder warrants (tegningsoptioner), eller yde lån til et eller flere unoterede erhvervsdrivende biomedicinske eller bioteknologiske selskaber fortrinsvis i Norden, England, Irland, Tyskland, Frankrig, Holland, Belgien og Luxembourg. Selskaberne kan eje såvel majoritets- som minoritetsposter i sådanne selskaber. Selskaberne kan anbringe ledig kapital i skandinaviske statsobligationer med kort løbetid, i statsgældsbeviser og som kontante indskud i pengeinstittutter. Yderligere kan selskaberne besidde aktier optaget til omsætning på et reguleret marked som følge af en optagelse til omsætning af et porteføljeselskabs aktier eller som vederlag i forbindelse med salg af porteføljeselskaber
Address
Bredgade 40
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 0 | 0 | 0 | 0 | 0 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | 0 | 0 | 0 | 0 | 0 |
| Net financials | -4.540 | -39 | -4 | 0 | 0 |
| Profit before tax | -4.540 | -39 | -4 | 0 | 0 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | -4.540 | -39 | -4 | 0 | 0 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2.901 | 12 | 8 | 8 | 8 |
| Equity | 2.901 | 12 | 8 | 8 | 8 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 0 | 0 |
| Total debt | 0 | 0 | 0 | 0 | 0 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20202024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20202024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20202024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AT Management | Management | 2023 |
| Former (7) | ||
KB Management | Management | 2014 – 2016 |
SF Management | Management | 2018 – 2019 |
BF Management | Management | 2010 – 2014 |
KH Management | Management | 2019 – 2023 |
TT Management | Management | 2009 – 2010 |
JZ Management | Management | 2004 – 2009 |
LT Management | Management | 2016 – 2018 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2014 | |
| Deputy Chairman | 2025 | |
| Former (10) | ||
| Board of Directors | 2004 – 2008 | |
| Board of Directors | 2004 – 2007 | |
| Chairman | 2004 – 2011 | |
| Board of Directors | 2011 – 2013 | |
| Chairman | 2011 – 2013 | |
| Board of Directors | 2011 – 2013 | |
| Deputy Chairman | 2011 – 2013 | |
| Deputy Chairman | 2014 – 2025 | |
| Board of Directors | 2011 – 2013 | |
| Board of Directors | 2007 – 2010 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 33.33–49.99% | 33.33–49.99% | 2008 | |
| Company | 15–19.99% | 15–19.99% | 2008 | |
| Company | 10–14.99% | 10–14.99% | 2008 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Frie Skolers LærerforeningLÆRERNES PENSION, FORSIKRINGSAKTIESELSKAB
K/S BI BIOMEDICAL VENTURE IV (this company)Board members of K/S BI BIOMEDICAL VENTURE IV also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kenneth Bering Hansen | Management | 0 companies |
| Sanne Fredenslund | Management | 0 companies |
| Bo Foged | Management | 0 companies |
| Kurt Hangaard | Management | 0 companies |
| Thomas Tscherning | Management | 0 companies |
| Jesper Zeuthen | Management | 0 companies |
| Ahmet Turan Kayhan | Management | 0 companies |
| Lars Thomas Gunnarsson | Management | 0 companies |
| Lars Kolind | Board of Directors | 0 companies |
| Asger Ib Mardahl-Hansen | Board of Directors | 0 companies |
| Uffe Ellemann-Jensen | Chairman | 0 companies |
| David Raymond Ansell | Board of Directors | 0 companies |
| David Richard Hexter | Chairman | 0 companies |
| Carl Jørgen Dan Jensen | Board of Directors | 0 companies |
| Andrea Panzieri | Chairman | 0 companies |
| Bent Pedersen | Deputy Chairman | 0 companies |
| Allan Funk Nissen | Deputy Chairman | 0 companies |
| Mikael Kortegaard Larsen | Deputy Chairman | 0 companies |
| Børge Obel | Board of Directors | 0 companies |
| Lars Christian Bruhn | Board of Directors | 0 companies |